Skip to main content
Study begins for Novocure's Optune device, Roche's Avastin

The first patient in a Phase II pilot study of a combination of Novocure's Optune tumor-treating fields delivery device and Roche Holding's Avastin has been enrolled. The 85-subject trial, which has a primary endpoint of overall survival at six months, seeks to assess use of the combined therapy for treating patients with refractory recurrent glioblastoma.

Full Story: